Isorhamnetin-7-glucoside for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Isorhamnetin-7-glucoside may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 12,000+ potential treatments.
c19early.org analyzes
220+ treatments.
We have not reviewed isorhamnetin-7-glucoside in detail.
, Evaluation of the Antiviral Activity of Cuscuta Extracts Against HSV-1, HSV-2 (ACV-Resistant Strain), HCoV229E and SARS-CoV-2, International Journal of Molecular Sciences, doi:10.3390/ijms27188120
The toxicological risk and development of resistance associated with synthetic drugs and supplements can be reduced by focusing efforts on medicinal plants that are of interest in pharmacognostic research to find new drugs or templates for the development of new bioactive compounds. The parasitic plant Cuscuta spp. has significant pharmacological activity at the extract level, but there is limited data on the bioactivity of its chemical compounds. In the present study, we aimed to investigate the antiviral potential of extracts obtained from different parts of two species, C. campestris and C. epithymum. The two species clearly differ in their flavonoid profiles, which could also suggest different antiviral activities of the extracts. We used methanol and aqueous extracts, MDBK, VERO E6 clone 76 and BGM cell lines, HSV-1, HSV-2 strain DD (acyclovir-resistant), HCoV-229E and SARS-CoV-2, maximum tolerable concentration, the MTT test, the plaque-forming method and the HPLS-MS analysis. It was found that the metabolic composition varies depending on the host plant. We hypothesize that differences in the composition of the extracts lead to differences in antiviral activity. Some of the tested methanol extracts showed a pronounced inhibitory effect, both on replication and on extracellular virions, in relation to the ACV-resistant strain of HSV type 2 and SARS-CoV-2 in comparison with the other viral models used by us. The strongest antiviral effect was shown by the methanol extract of C. campestris with host Chenopodium spp. against SARS-CoV-2, as the virus inhibition was about 100%, and the virucidal effect showed a decrease in the viral titer by more than 2.5 lg. Based on the results obtained, we assume possible antagonistic interaction of individual metabolites in the total methanol extracts. Extract C3, applied at the maximum tolerable concentration and one level lower, inhibits SARS-CoV-2 about 100 percent. SARS-CoV-2-infected cells preserved mitochondrial activity and relatively preserved lysosomal activity; this is also the reason why the MTT test, as well as neutral red staining, is not applicable to this viral model propagated in the VERO E6 cell line.